GalNAc-T17 Activators
GalNAc-T17 activators are a chemical class that pertains to the regulation of a specific type of enzyme known as GalNAc-T17, which is a member of the polypeptide N-acetylgalactosaminyltransferase (GalNAc-T) family. The enzymes in this family are primarily involved in initiating the process of O-glycosylation, where a carbohydrate molecule, specifically N-acetylgalactosamine (GalNAc), is attached to the hydroxyl group of a serine or threonine residue in a polypeptide chain. This post-translational modification is crucial for a multitude of cellular processes, including protein folding, stability, and cell signaling. GalNAc-T17 activators, therefore, interact with the GalNAc-T17 enzyme to modulate its activity. The precise mechanisms through which these activators exert their function involve complex molecular interactions that enhance the enzyme's affinity for its substrates or increase its catalytic efficiency.
The biochemical pathways influenced by GalNAc-T17 are intricate and have significant roles in cellular communication and function. The GalNAc-T17 enzyme itself is characterized by its unique substrate specificities and expression patterns within the body. The role of GalNAc-T17 activators is to modulate the enzymatic action of GalNAc-T17, which implies that they may play a role in influencing the glycosylation patterns of proteins. This alteration in glycosylation can, in turn, affect a multitude of protein interactions and functions. The activators are typically small molecules that can cross cell membranes and interact with the enzyme in the Golgi apparatus, where O-glycosylation primarily occurs. By modulating the activity of GalNAc-T17, these activators can have significant downstream effects on the overall profile of glycoproteins produced within a cell, which may have diverse implications for cellular behavior and the maintenance of homeostasis.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Manganese(II) chloride beads | 7773-01-5 | sc-252989 sc-252989A | 100 g 500 g | $19.00 $31.00 | ||
Manganese ions are essential cofactors for many glycosyltransferases. Manganese (II) chloride provides these ions, which bind to GalNAc-T17, inducing a conformational change that enhances its enzymatic activity. | ||||||
N-Acetyl-D-galactosamine | 1811-31-0 | sc-221979 sc-221979A sc-221979C sc-221979B sc-221979D | 10 mg 100 mg 1 g 5 g 50 g | $51.00 $77.00 $267.00 $1040.00 $1326.00 | ||
As a substrate for GalNAc-T17, the presence of N-Acetylgalactosamine directly increases the glycosyltransferase activity by serving as the sugar donor for O-glycosylation reactions, which GalNAc-T17 catalyzes. | ||||||
Benzyl-2-acetamido-2-deoxy-α-D-galactopyranoside | 3554-93-6 | sc-203427 sc-203427A | 100 mg 1 g | $350.00 $3184.00 | 2 | |
This thiol-linked sugar analog serves as a competitive inhibitor for some glycosyltransferases but can enhance GalNAc-T17 activity by being used as an alternative substrate, thus facilitating the enzyme's glycosyltransferase action. | ||||||
2-Deoxy-D-galactose | 1949-89-9 | sc-202400 sc-202400A sc-202400B | 1 g 5 g 25 g | $81.00 $302.00 $1436.00 | ||
Deoxy-D-galactose acts as a substrate analog for glycosyltransferases and can enhance the activity of GalNAc-T17 by binding and orienting the enzyme for efficient catalysis of glycosylation reactions. | ||||||
Thiamet G | 1009816-48-1 | sc-224307 sc-224307A | 1 mg 5 mg | $52.00 $96.00 | 1 | |
Thiamet G inhibits O-GlcNAcase, leading to increased O-GlcNAcylation levels. This may indirectly enhance the activity of GalNAc-T17 by elevating the overall glycosylation state within the cell, which can affect substrate availability. | ||||||
Kifunensine | 109944-15-2 | sc-201364 sc-201364A sc-201364B sc-201364C | 1 mg 5 mg 10 mg 100 mg | $135.00 $540.00 $1025.00 $6248.00 | 25 | |
Kifunensine is a mannosidase inhibitor that can lead to an accumulation of high-mannose glycoproteins. These glycoproteins can then serve as substrates for GalNAc-T17, potentially enhancing its activity by increasing substrate availability. | ||||||
Swainsonine | 72741-87-8 | sc-201362 sc-201362C sc-201362A sc-201362D sc-201362B | 1 mg 2 mg 5 mg 10 mg 25 mg | $138.00 $251.00 $631.00 $815.00 $1832.00 | 6 | |
Swainsonine inhibits Golgi alpha-mannosidase II, leading to an increase in hybrid-type N-glycans, which may become substrates for further modification by GalNAc-T17, thereby enhancing its glycosylation activity. | ||||||
Castanospermine | 79831-76-8 | sc-201358 sc-201358A | 100 mg 500 mg | $184.00 $632.00 | 10 | |
As an inhibitor of glucosidases, Castanospermine can result in the accumulation of glycoproteins with incomplete glycan processing, which may serve as substrates for GalNAc-T17, potentially increasing its enzymatic activity. | ||||||
Deoxynojirimycin | 19130-96-2 | sc-201369 sc-201369A | 1 mg 5 mg | $73.00 $145.00 | ||
DMJ is an alpha-mannosidase inhibitor that can lead to the buildup of misfolded glycoproteins. These glycoproteins may be recognized and further modified by GalNAc-T17, indirectly enhancing the enzyme's glycosylation function. | ||||||